Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania and currently employs 528 full-time employees. The company went IPO on 2007-02-06. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Follow-Up Questions
Madrigal Pharmaceuticals Inc의 CEO는 누구입니까?
Mr. Bill Sibold은 2023부터 회사에 합류한 Madrigal Pharmaceuticals Inc의 President입니다.
MDGL 주식의 가격 성능은 어떻습니까?
MDGL의 현재 가격은 $421.51이며, 전 거래일에 increased 0% 하였습니다.
Madrigal Pharmaceuticals Inc의 주요 사업 주제나 업종은 무엇입니까?
Madrigal Pharmaceuticals Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Madrigal Pharmaceuticals Inc의 시가총액은 얼마입니까?
Madrigal Pharmaceuticals Inc의 현재 시가총액은 $9.3B입니다
Madrigal Pharmaceuticals Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 17명의 분석가가 Madrigal Pharmaceuticals Inc에 대한 분석 평가를 실시했으며, 이는 6명의 강력한 매수, 13명의 매수, 2명의 보유, 1명의 매도, 그리고 6명의 강력한 매도를 포함합니다
